NASDAQ:SIBN

SI-BONE (SIBN) Stock Forecast, Price & News

$21.15

-0.06 (-0.28%)

(As of 09/22/2023 ET)

Compare

Today's Range: $20.65
▼
$21.93
50-Day Range: $20.22
▼
$26.48
52-Week Range: $11.14
▼
$29.51

Volume: 227,089 shs
Average Volume: 296,983 shs
Market Capitalization: $818.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.00

SI-BONE MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 32.4% Upside
$28.00 Price Target
Short Interest: Healthy
1.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.44
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$2.09 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.25) to ($0.93) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

211th out of 963 stocks

Surgical & Medical Instruments Industry

26th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
SI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.00, SI-BONE has a forecasted upside of 32.4% from its current price of $21.15.
Amount of Analyst Coverage
SI-BONE has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.92% of the outstanding shares of SI-BONE have been sold short.
Short Interest Ratio / Days to Cover
SI-BONE has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SI-BONE has recently decreased by 22.32%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
SI-BONE does not currently pay a dividend.
Dividend Growth
SI-BONE does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
SI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.
Environmental Sustainability
The Environmental Impact score for SI-BONE is -1.44.

3.2

News and Social Media Coverage

News Sentiment
SI-BONE has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for SI-BONE this week, compared to 1 article on an average week.
Search Interest
6 people have searched for SIBN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added SI-BONE to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,094,563.00 in company stock.
Percentage Held by Insiders
Only 5.40% of the stock of SI-BONE is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SI-BONE are expected to grow in the coming year, from ($1.25) to ($0.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SI-BONE is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SI-BONE is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SI-BONE has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SI-BONE (NASDAQ:SIBN) Stock

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Price History

30 days | 90 days | 365 days | Advanced Chart

SIBN Stock News Headlines

September 8, 2023 | finance.yahoo.com

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?

September 6, 2023 | finance.yahoo.com

Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 5, 2023 | finance.yahoo.com

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods

August 31, 2023 | msn.com

SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy

August 29, 2023 | finance.yahoo.com

SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023

August 27, 2023 | msn.com

Morgan Stanley bullish on SI-Bone, downgrades Stevanato, Integra, Agiliti

August 9, 2023 | finance.yahoo.com

SI-BONE, Inc. (NASDAQ:SIBN) Q2 2023 Earnings Call Transcript

September 24, 2023 | Chaikin Analytics (Ad)

Holding NVDA? Read This Now

NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. Learn more here.

August 9, 2023 | msn.com

Cantor Fitzgerald Reiterates SI-BONE (SIBN) Overweight Recommendation

August 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: SI-Bone (SIBN) and Enanta Pharmaceuticals (ENTA)

August 8, 2023 | finance.yahoo.com

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance

July 19, 2023 | msn.com

Truist Securities Maintains SI-BONE (SIBN) Buy Recommendation

July 19, 2023 | finance.yahoo.com

SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023

July 17, 2023 | finance.yahoo.com

SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023

July 16, 2023 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)

July 12, 2023 | msn.com

Needham Maintains SI-BONE (SIBN) Buy Recommendation

July 12, 2023 | markets.businessinsider.com

SI-BONE Poised For A Surge: Analyst Highlights Upside Potential With New Product Launches

July 7, 2023 | fool.com

Si-bone (NASDAQ: SIBN)

June 15, 2023 | msn.com

SI-BONE: Rating Higher On Fundamental, Economic Grounds

June 14, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Bioxcel Therapeutics (BTAI), SI-Bone (SIBN)

May 31, 2023 | msn.com

Morgan Stanley Maintains SI-BONE (SIBN) Overweight Recommendation

May 29, 2023 | finance.yahoo.com

Despite shrinking by US$86m in the past week, SI-BONE (NASDAQ:SIBN) shareholders are still up 69% over 1 year

May 24, 2023 | finance.yahoo.com

SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023

May 10, 2023 | msn.com

Unusual Call Option Trade in SI-BONE (SIBN) Worth $65.00K

May 2, 2023 | finance.yahoo.com

Why Shares of Si-Bone Jumped Tuesday

April 24, 2023 | finance.yahoo.com

SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference

See More Headlines

Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SIBN Company Calendar

Last Earnings: 8/07/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SIBN
CUSIP: N/A
CIK: 1459839
Web: www.si-bone.com
Phone: (408) 207-0700
Fax: N/A
Employees: 357
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $28.00
High Stock Price Forecast: $33.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +32.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,260,000.00
Net Margins: -38.32%
Pretax Margin: -38.32%
Return on Equity: -40.35%
Return on Assets: -27.29%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 11.68
Quick Ratio: 10.55

Sales & Book Value

Annual Sales: $106.41 million
Price / Sales: 7.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.85 per share
Price / Book: 7.42

Miscellaneous

Outstanding Shares: 38,690,000
Free Float: 36,597,000
Market Cap: $818.29 million
Optionable: Not Optionable
Beta: 0.95

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Ms. Laura A. Francis MBA (Age 56)
CEO & Director
Comp: $1.11M

Mr. Anshul Maheshwari (Age 43)
Chief Financial Officer
Comp: $614.25k

Mr. Anthony J. Recupero (Age 64)
Pres of Commercial Operations
Comp: $795.32k

Mr. Jeff Bertolini
Sr. VP of Operations & Information Technology

Dr. Scott A. Yerby (Age 55)
Sr. VP of Engineering & CTO

Mr. Michael A. Pisetsky (Age 45)
Chief Bus. & Legal Affairs Officer

Ms. Aimee Einstein
VP of People & Culture

Dr. Daniel Joseph Cher (Age 58)
Sr. VP of Clinical & Regulatory Affairs

Dr. W. Carlton Reckling (Age 61)
Chief Medical Officer & VP of Medical Affairs

Mr. Nikolas F. Kerr (Age 51)
Sr. VP of Product, Strategy & Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SIBN Stock - Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.
What is SI-BONE's stock price forecast for 2023?: 7 brokerages have issued 12 month price targets for SI-BONE's stock. Their SIBN share price forecasts range from $20.00 to $33.00. On average, they predict the company's share price to reach $28.00 in the next year. This suggests a possible upside of 32.4% from the stock's current price.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.
How have SIBN shares performed in 2023?: SI-BONE's stock was trading at $13.60 on January 1st, 2023. Since then, SIBN shares have increased by 55.5% and is now trading at $21.15.
View the best growth stocks for 2023 here.
Are investors shorting SI-BONE?: SI-BONE saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 742,500 shares, a drop of 22.3% from the August 15th total of 955,900 shares. Based on an average trading volume of 375,000 shares, the days-to-cover ratio is presently 2.0 days.
View SI-BONE's Short Interest.
When is SI-BONE's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our SIBN earnings forecast.
How were SI-BONE's earnings last quarter?: SI-BONE, Inc. (NASDAQ:SIBN) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.11. The company earned $33.31 million during the quarter, compared to analysts' expectations of $32.24 million. SI-BONE had a negative net margin of 38.32% and a negative trailing twelve-month return on equity of 40.35%.
What guidance has SI-BONE issued on next quarter's earnings?: SI-BONE updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $132.00 million-$134.00 million, compared to the consensus revenue estimate of $130.03 million.
What is Jeffrey Dunn's approval rating as SI-BONE's CEO?: 10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).
When did SI-BONE IPO?: (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
What is SI-BONE's stock symbol?: SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."
Who are SI-BONE's major shareholders?: SI-BONE's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (11.23%), BlackRock Inc. (7.57%), Silvercrest Asset Management Group LLC (2.62%), Granahan Investment Management LLC (2.44%), State Street Corp (2.38%) and Divisadero Street Capital Management LP (2.35%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends.
How do I buy shares of SI-BONE?: Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is SI-BONE's stock price today?: One share of SIBN stock can currently be purchased for approximately $21.15.
How much money does SI-BONE make?: SI-BONE (NASDAQ:SIBN) has a market capitalization of $818.29 million and generates $106.41 million in revenue each year. The company earns $-61,260,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.
How many employees does SI-BONE have?: The company employs 357 workers across the globe.
Does SI-BONE have any subsidiaries?: The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.
Read More
How can I contact SI-BONE?: SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for the company is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.

This page (NASDAQ:SIBN) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial